POLYPEPTIDE ANTAGONISTS OF HUMAN IL-23 RECEPTOR FOR TREATMENT OF AUTOIMMUNE DISEASES
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F17%3A00470240" target="_blank" >RIV/61388971:_____/17:00470240 - isvavai.cz</a>
Alternative codes found
RIV/86652036:_____/17:00470240
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/biblio?II=0&ND=3&adjacent=true&locale=cz_CZ&FT=D&date=20150930&CC=EP&NR=2922560A1&KC=A1#" target="_blank" >https://worldwide.espacenet.com/publicationDetails/biblio?II=0&ND=3&adjacent=true&locale=cz_CZ&FT=D&date=20150930&CC=EP&NR=2922560A1&KC=A1#</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
POLYPEPTIDE ANTAGONISTS OF HUMAN IL-23 RECEPTOR FOR TREATMENT OF AUTOIMMUNE DISEASES
Original language description
The present invention provides a novel class of polypeptides (REX binders), derived from an albumin-binding domain of the streptococcal protein G that inhibit binding of human IL-23 cytokine to its cognate IL-23 receptor. Blocking of interaction between p19/IL-23 subunit with the receptor leads to the suppresion of IL-23-dependent pro-inflammatory signaling pathway, resulting in an inhibitory effect on IL-23-stimulated Th-17 cell expansion. The invention further provides a DNA sequence encoding for such polypeptides and host cells containing such sequence. The polypeptides of the invention are useful as therapeutics and diagnostics.˙
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
EE - Microbiology, virology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
EP2922560
Publisher
EPO_1 -
Publisher name
European Patent Office
Place of publication
Munich, The Hague, Berlin, Vienna, Brussels
Publication country
—
Date of acceptance
Jan 4, 2017
Owner name
Biotechnologický ústav AV ČR, v. v. i.
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence